Abstract
Musculoskeletal metabolic diseases such as osteoporosis have become the major public health problems worldwide in our aging society. Pharmaceutical therapy is one of the approaches to prevent and treat related medical conditions. Most of the clinically used anti-osteoporotic drugs are administered systemically and have demonstrated some side effects in non-skeletal tissues. One of the innovative approaches to prevent potential adverse effects is the development of bone-targeting drug delivery technologies that not only minimizes the systemic toxicity but also improves the pharmacokinetic profile and therapeutic efficacy of chemical drugs. This paper reviews the currently available bone targeting drug delivery systems with emphasis as bone-targeting moieties, including the bonesurface- site-specific (bone formation dominant or bone resorption dominant) and cell-specific moieties. In addition, the connections of drug-bone-targeting moieties-carrier are also summarized, and the newly developed liposomes and nanoparticles are discussed for their potential use and main challenges in delivering therapeutic agents to bone tissue. As a rapid-developing biotechnology, systemic bonetargeting delivery system is promising but still in its infancy where challenges are ahead of us, including the stability and the toxicity issues, especially to fulfill the regulatory requirement to realize bench-to-bedside translation. Newly developed biomaterials and technologies with potential for safer and more effective drug delivery require multidisciplinary collaborations with preclinical and clinical scientists that are essential to facilitate their clinical applications.
Keywords: Bone-targeting, systemic drug delivery system, liposomes, nanoparticles.
Current Pharmaceutical Design
Title:Systemic Drug Delivery Systems for Bone Tissue Regeneration– A Mini Review
Volume: 21 Issue: 12
Author(s): Wang Xinluan, Lai Yuxiao, Ng HueiLeng Helena, Yang Zhijun and Qin Ling
Affiliation:
Keywords: Bone-targeting, systemic drug delivery system, liposomes, nanoparticles.
Abstract: Musculoskeletal metabolic diseases such as osteoporosis have become the major public health problems worldwide in our aging society. Pharmaceutical therapy is one of the approaches to prevent and treat related medical conditions. Most of the clinically used anti-osteoporotic drugs are administered systemically and have demonstrated some side effects in non-skeletal tissues. One of the innovative approaches to prevent potential adverse effects is the development of bone-targeting drug delivery technologies that not only minimizes the systemic toxicity but also improves the pharmacokinetic profile and therapeutic efficacy of chemical drugs. This paper reviews the currently available bone targeting drug delivery systems with emphasis as bone-targeting moieties, including the bonesurface- site-specific (bone formation dominant or bone resorption dominant) and cell-specific moieties. In addition, the connections of drug-bone-targeting moieties-carrier are also summarized, and the newly developed liposomes and nanoparticles are discussed for their potential use and main challenges in delivering therapeutic agents to bone tissue. As a rapid-developing biotechnology, systemic bonetargeting delivery system is promising but still in its infancy where challenges are ahead of us, including the stability and the toxicity issues, especially to fulfill the regulatory requirement to realize bench-to-bedside translation. Newly developed biomaterials and technologies with potential for safer and more effective drug delivery require multidisciplinary collaborations with preclinical and clinical scientists that are essential to facilitate their clinical applications.
Export Options
About this article
Cite this article as:
Xinluan Wang, Yuxiao Lai, Helena HueiLeng Ng, Zhijun Yang and Ling Qin, Systemic Drug Delivery Systems for Bone Tissue Regeneration– A Mini Review, Current Pharmaceutical Design 2015; 21 (12) . https://dx.doi.org/10.2174/1381612821666150115152841
DOI https://dx.doi.org/10.2174/1381612821666150115152841 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Differentiation Potential of Human Retinoblastoma Cells
Current Pharmaceutical Biotechnology Role of Angiopoietin-like 4 (ANGPTL4), a Member of Matricellular Proteins: from Homeostasis to Inflammation and Cancer Metastasis
Current Angiogenesis (Discontinued) Irinotecan for Treatment of Childhood Cancers: A Promising Therapeutic Partner
Current Cancer Therapy Reviews Evidence for Predominance of CCR5-Using HIV-1 Strains During Highly Active Antiretroviral Therapy
Current HIV Research Editorial
Recent Patents on Anti-Cancer Drug Discovery Fluoride Effects: The Two Faces of Janus
Current Medicinal Chemistry Anti-tumor Activity of Propofol: A Focus on MicroRNAs
Current Cancer Drug Targets Facile Synthesis of Stereoisomers of the Non-Secosteroidal Ligand LG190178 and their Evaluation Using the Mutant Vitamin D Receptor
Letters in Organic Chemistry Subject Index To Volume 6
Current Molecular Medicine Mesenchymal Stem Cells Regulate Cytoskeletal Dynamics and Promote Cancer Cell Invasion Through Low Dose Nitric Oxide
Current Molecular Medicine Cellular Toxicity and Apoptosis Studies in Osteocarcinoma Cells, a Comparison of 177Lu-EDTMP and Lu-EDTMP
Current Radiopharmaceuticals The Water Channels, New Druggable Targets to Combat Cancer Cell Survival,Invasiveness and Metastasis
Current Drug Targets Regulation of HIPK Proteins by MicroRNAs
MicroRNA Oligonucleotides as Anticancer Agents: From the Benchside to the Clinic and Beyond
Current Pharmaceutical Design High-Content Analysis of Kinase Activity in Cells
Combinatorial Chemistry & High Throughput Screening Vitamin D and miRNAs in Cancer
Current Gene Therapy Gene Therapy Approaches for the Selective Killing of Cancer Cells
Current Pharmaceutical Design Targeting MDM4 as a Novel Therapeutic Approach for Hematologic Malignancies
Current Cancer Drug Targets Development of Patents and Clinical Trials on Regenerative Therapy: Gene Therapy
Recent Patents on Regenerative Medicine Protective Effects of Melatonin and Mitochondria-targeted Antioxidants Against Oxidative Stress: A Review
Current Medicinal Chemistry